A Multi-Analyte cfDNA-Based Blood Test for Early Detection of Hepatocellular Carcinoma
The pivotal CLiMB trial. HelioLiver detected liver cancer earlier than ultrasound in a large, prospective US study of high-risk patients.

For over a decade, Helio's science has been published in some of the world's most respected peer-reviewed journals. Explore the research behind HelioLiver and the platform that powers it.
Helio Genomics was built on a simple idea: that the patterns hidden in cell-free DNA could reveal cancer earlier than ever before. The papers below trace that journey, from foundational research on DNA methylation and human aging, through validation across multiple cancers, to the pivotal CLiMB trial behind HelioLiver. Together they represent the rigorous, published science that underpins everything we do.
cfDNA methylation research

Helio Genomics was built on a simple idea: that the patterns hidden in cell-free DNA could reveal cancer earlier than ever before.
The science behind HelioLiver
Peer-reviewed research from foundational methylation studies to the pivotal trials behind HelioLiver and the Helio platform.
The pivotal CLiMB trial. HelioLiver detected liver cancer earlier than ultrasound in a large, prospective US study of high-risk patients.
A multimodal sequencing approach for non-invasive colorectal cancer detection.
Clinical validation of the colorectal cancer screening test in a high-risk population.
The ENCORE study. Clinical validation of the HelioLiver product for early HCC detection.
An advanced bioinformatics algorithm that strengthens how methylation data predicts gene expression, part of the science behind Helio's platform.
A large-scale clinical study of cfDNA methylation markers in the detection of colorectal cancer (CRC).
A large-scale clinical study across liver, colon, lung, and breast cancers, validating new DNA methylation markers.
A large-scale clinical study of cfDNA methylation markers in the detection of HCC.
A large-scale clinical study on cfDNA methylation in relation to aging and age-related diseases, where Helio's science began.
These publications underpin the HelioLiver test and the broader Helio platform. To dig deeper into our clinical evidence or to discuss the science with our team, we'd be glad to hear from you.